SEC Filing Summary: pSivida Limited (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by pSivida Limited, a foreign issuer with principal executive offices in Perth, Western Australia, for the month of June 2006. The filing was signed on June 7, 2006, by Aaron Finlay, Company Secretary. The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a specific corporate event rather than a financial statement.
Material Changes
The primary material event disclosed is the receipt of government approvals for international clinical Phase III trials for the company's MedidurTM Diabetic Macular Edema Programme. This information is detailed in Exhibit 99.1 attached to the filing.
Guidance, Outlook, and Risks
The filing text does not provide specific financial guidance, management commentary on future performance, or a detailed discussion of risks and contingencies beyond the context of the clinical trial approvals.
Key Facts for Investor Verification
- Verify the specific jurisdictions where government approvals for the MedidurTM Phase III trials were granted.
- Confirm the timeline and scope of the international clinical Phase III trials for Diabetic Macular Edema.
- Review the full text of Exhibit 99.1 for details on the regulatory approvals.